At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 249 enrolled
Drug / intervention
Mirikizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
In Brief
A Phase 2 clinical trial evaluating Mirikizumab and Placebo for Ulcerative Colitis. Completed, enrolled 249 participants across 76 sites in 16 countries.
Detailed Summary
The main purpose of this study is to test the hypothesis that treatment with mirikizumab is superior to placebo in providing clinical benefit to participants with moderate to severe ulcerative colitis (UC). This study will also investigate how the body processes the drug.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesAustralia, Belgium, Canada, Czechia, Denmark, France, Georgia, Hungary, Japan, Lithuania, Moldova, Netherlands, Poland, Romania, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartDec 2015
Primary CompletionDec 2017
Study CompletionMay 2019
TodayJul 2026
First PostedOct 28, 2015
Enrollment StartDec 9, 2015
Primary CompletionDec 19, 2017
Study CompletionMay 7, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.7 years ago
Interventions
Mirikizumabdrug
Placebodrug